Tech Company Financing Transactions
CellCentric Funding Round
CellCentric, operating out of Kirchheim, secured $25 million from Pfizer Venture Investments.
Transaction Overview
Company Name
Announced On
7/24/2023
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Neue Strasse 95 Industriepark Nabern
Kirchheim, 73230
DE
Kirchheim, 73230
DE
Phone
Undisclosed
Website
Email Address
Overview
CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat multiple specific cancer types. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthias Jurytko
Chief Financial Officer
Niklas Ekström
Browse more venture capital transactions:
Prev: 7/24/2023: Snowstorm venture capital transaction
Next: 7/24/2023: Ati Motors venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs